132 related articles for article (PubMed ID: 3181817)
1. Intravascular coagulation phenomena associated with prevalent fall in fibrinogen and plasminogen during L-asparaginase treatment in leukemic children.
Legnani C; Palareti G; Pession A; Poggi M; Vecchi V; Bianchini B; Coccheri S
Haemostasis; 1988; 18(3):179-86. PubMed ID: 3181817
[TBL] [Abstract][Full Text] [Related]
2. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study.
Mazzucconi MG; Gugliotta L; Leone G; Dragoni F; Belmonte MM; De Stefano V; Chistolini A; Tura S; Mandelli F
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):23-8. PubMed ID: 7514043
[TBL] [Abstract][Full Text] [Related]
3. Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy.
Saito M; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Ito K; Matsuda T
Am J Hematol; 1989 Sep; 32(1):20-3. PubMed ID: 2757000
[TBL] [Abstract][Full Text] [Related]
4. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia.
Zaunschirm A; Muntean W
Pediatr Hematol Oncol; 1986; 3(1):19-25. PubMed ID: 3153215
[TBL] [Abstract][Full Text] [Related]
5. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
6. Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation.
Rodeghiero F; Castaman G; Dini E
Thromb Res; 1990 Jan; 57(1):31-8. PubMed ID: 2300923
[TBL] [Abstract][Full Text] [Related]
7. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.
Risseeuw-Appel IM; Dekker I; Hop WC; Hählen K
Med Pediatr Oncol; 1994; 23(4):335-43. PubMed ID: 8058004
[TBL] [Abstract][Full Text] [Related]
8. [Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols].
Sutor AH; Niemeyer C; Sauter S; Witt I; Kaufmehl K; Rombach A; Brandis M; Riehm H
Klin Padiatr; 1992; 204(4):264-73. PubMed ID: 1518263
[TBL] [Abstract][Full Text] [Related]
9. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
[TBL] [Abstract][Full Text] [Related]
10. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation.
Nowak-Göttl U; Ahlke E; Schulze-Westhoff P; Boos J
Br J Haematol; 1996 Oct; 95(1):123-6. PubMed ID: 8857948
[TBL] [Abstract][Full Text] [Related]
11. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase.
Mattioli Belmonte M; Gugliotta L; Delvos U; Catani L; Vianelli N; Cascione ML; Belardinelli AR; Mottola L; Tura S
Haematologica; 1991; 76(3):209-14. PubMed ID: 1743591
[TBL] [Abstract][Full Text] [Related]
12. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
Merlen C; Bonnefoy A; Wagner E; Dedeken L; Leclerc JM; Laverdière C; Rivard GE
Pediatr Blood Cancer; 2015 Aug; 62(8):1381-7. PubMed ID: 25820776
[TBL] [Abstract][Full Text] [Related]
13. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
[TBL] [Abstract][Full Text] [Related]
14. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia.
Priest JR; Ramsay NK; Bennett AJ; Krivit W; Edson JR
J Pediatr; 1982 Jun; 100(6):990-5. PubMed ID: 6953222
[TBL] [Abstract][Full Text] [Related]
15. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
Beinart G; Damon L
Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
[TBL] [Abstract][Full Text] [Related]
16. Coagulopathic side effect of L-asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase.
Alqasim AMZ; Al-Hadithi RH; Al-Khalidi AN
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):67-69. PubMed ID: 29406239
[TBL] [Abstract][Full Text] [Related]
17. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
18. Antithrombin and fibrinogen levels as predictors for plasma L-asparaginase activity in children with acute lymphoblastic leukemia.
Merlen C; Bonnefoy A; Afeich C; Théorêt Y; Laverdière C; Leclerc JM; Rivard GE
Pediatr Blood Cancer; 2019 Jul; 66(7):e27729. PubMed ID: 30938058
[TBL] [Abstract][Full Text] [Related]
19. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
Ranta S; Heyman MM; Jahnukainen K; Taskinen M; Saarinen-Pihkala UM; Frisk T; Söderhäll S; Petrini P; Mäkipernaa AM
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):749-56. PubMed ID: 24056293
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis in children receiving L-asparaginase. Determining patients at risk.
Shapiro AD; Clarke SL; Christian JM; Odom LF; Hathaway WE
Am J Pediatr Hematol Oncol; 1993 Nov; 15(4):400-5. PubMed ID: 8214362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
